Brief: Nordic Nanovector Completes Patient Enrolment In Phase 1 Trial Of Betalutin In Diffuse Large B-Cell Lymphoma
July 11 (Reuters) - Nordic Nanovector ASA NANOV.OL :
* NORDIC NANOVECTOR COMPLETES PATIENT ENROLMENT INTO PHASE 1
TRIAL
OF BETALUTIN® IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
* NORDIC NANOVECTOR ASA - PRELIMINARY RESULTS ARE EXPECTED
IN
SECOND HALF OF 2019
Source text for Eikon: ID:nPn2mhFcNa
Further company coverage: NANOV.OL
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Thor Medical ASA
See all newsBrief: Thor Medical Cancels Subsequent Offering
Brief: Thor Medical Mulls Private Placement And Retail Offering
Brief: Thor Medical CFO Brede Ellingsæter To Transition To Chief Operating Officer
Brief: Thor Medical Enters Partnership Agreement With Minerva Imaging
Brief: Thor Medical Partners With Eckert & Ziegler